World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
81865
World Ranking
11938
National Ranking
1131

Overview

Andrew Tutt is affiliated with the Institute of Cancer Research in the United Kingdom. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with a concentration on Oncology, Molecular Biology, Cancer Research, Genetics, and Pulmonary and Respiratory Medicine.

The scientist's research topics include:

  • PARP inhibition in cancer therapy
  • DNA Repair Mechanisms
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • CRISPR and Genetic Engineering
  • Advanced Breast Cancer Therapies

Andrew Tutt has published extensively in the following venues:

  • Cancer Research
  • Annals of Oncology
  • npj Breast Cancer
  • Clinical Cancer Research
  • Journal of Clinical Oncology

Frequent co-authors with whom they have collaborated include:

  • Syed Haider
  • Stephen J. Pettitt
  • Christopher J. Lord
  • Judith M. Bliss
  • Rachel Brough

Some of the recent papers authored by Andrew Tutt include:

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer, 2021, New England Journal of Medicine
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, 2022, Annals of Oncology
  • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance, 2021, Nature Communications
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology

Best Publications

  • Signatures of mutational processes in human cancer

    Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio

  • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Hannah Farmer;Nuala McCabe;Christopher J. Lord;Andrew N. J. Tutt;Andrew N. J. Tutt

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences

    Serena Nik-Zainal;Serena Nik-Zainal;Helen Davies;Johan Staaf;Manasa Ramakrishna

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer

    A Tutt;M Robson;J E Garber;S M Domchek

  • Mutational Processes Molding the Genomes of 21 Breast Cancers

    Serena Nik-Zainal;Ludmil B. Alexandrov;David C. Wedge;Peter Van Loo;Peter Van Loo;Peter Van Loo

  • The landscape of cancer genes and mutational processes in breast cancer

    Philip J. Stephens;Patrick S. Tarpey;Helen Davies;Peter Van Loo;Peter Van Loo

  • Hallmarks of 'BRCAness' in sporadic cancers

    Nicholas Turner;Andrew Tutt;Alan Ashworth

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • The Life History of 21 Breast Cancers

    Serena Nik-Zainal;Peter Van Loo;Peter Van Loo;Peter Van Loo;David C. Wedge;Ludmil B. Alexandrov

  • Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

    Nuala McCabe;Nicholas C. Turner;Christopher J. Lord;Katarzyna Kluzek

  • Triple negative tumours : a critical review

    J S Reis-Filho;Andrew Tutt;Andrew Tutt

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

    Helen Davies;Dominik D. Glodzik;Sandro S. Morganella;Lucy R. Yates

Frequent Co-Authors

Alan Ashworth
Alan Ashworth University of California, San Francisco
Christopher J. Lord
Christopher J. Lord Institute of Cancer Research
Sarah E Pinder
Sarah E Pinder King's College London
Peter J. Campbell
Peter J. Campbell Wellcome Sanger Institute
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Tony Ng
Tony Ng King's College London
Anne Lise Børresen-Dale
Anne Lise Børresen-Dale Oslo University Hospital
Andrea L. Richardson
Andrea L. Richardson Johns Hopkins University
Judith M. Bliss
Judith M. Bliss Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but aren't pursuing a traditional MD, a wide range of online healthcare degrees and career options are available. For those interested in nursing, pursuing the cheapest rn to bsn program can be a practical way to advance your credentials while saving on tuition costs.

Applicants with non-nursing backgrounds might find direct entry online msn programs especially appealing, as they allow entry into advanced nursing without a prior nursing degree. Alternatively, online adn programs for non nurses provide an accessible path for those looking to break into the nursing profession more quickly.

If patient care isn’t your main interest, you might consider the administrative and technology side of healthcare. Curious about financial options? Find out can you get financial aid for medical billing and coding online programs, which can lead to in-demand roles supporting medical practices.

Best Scientists Citing Andrew Tutt

Trending Scientists